FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications

FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression

FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection

COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.

J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen